Saturday, February 11, 2017

Sonoma Pharmaceuticals Appoints Marc Umscheid as Chief Strategy and Marketing Officer






Source:  Sonoma Pharmaceuticals, Inc.


Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced the appointment of Marc Umscheid as chief strategy and marketing officer.  Previously, Umscheid worked at the Clorox Company where he most recently served as senior marketing director and business development team leader.

As CSO/CMO at Sonoma, Umscheid will direct overall global strategy and marketing efforts while facilitating continued revenue growth across the Sonoma Pharmaceutical product portfolio, which includes dermatology, advanced wound care and animal healthcare products.  Umscheid will report directly to Sonoma CEO Jim Schutz.

“Marc's expertise in global marketing and business development at a respected consumer products company makes him a fantastic addition to our fast-growing company,” said Jim Schutz, Sonoma CEO.  “His proven record of building brands organically as well as vetting acquisition and partnerships opportunities makes him an ideal fit for Sonoma Pharmaceuticals.  We expect Marc to help us focus on nearer-term profitability while continuing our strong growth in the prescription dermatology market.”

Umscheid is a graduate of Cornell University, where he received both a BS in business management/finance and an MBA from the Johnson Graduate School of Management.
Sonoma Pharmaceuticals initiated a strategic turnaround plan in April 2014, at which time the company installed new members to the board of directors, appointed a new CEO and continued to expand the company’s seasoned dermatology sales team. The company’s current product portfolio consists primarily of dermatology and advanced tissue care products based upon the company’s two proprietary and patented technologies, Microcyn® and Lipogrid®.

About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com

No comments:

Post a Comment